Results 221 to 230 of about 453,251 (315)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy. [PDF]

Inflamm Res
Chen P, Long J, Zhang J, Xie F, Wu W, Tian Z, Zhang S, Yu K.   +7 more
europepmc   +1 more source

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

Cancer Science, EarlyView.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu, Mengzhu Chinn, Feng Chen, Yerkezhan Yerkinkazhina, Yuan Tian, Wei‐Guo Zhu   +5 more
wiley   +1 more source

Periodontal diseases and adverse pregnancy outcomes. Present and future

Periodontology 2000, EarlyView., 2023
Abstract For more than two decades the possible association between periodontal diseases and adverse pregnancy outcomes has been extensively evaluated. Numerous observational, intervention, and mechanistic studies have offered valuable information on this topic.
Yiorgos A. Bobetsis, Mark Ide, Mervi Gürsoy, Phoebus N. Madianos   +3 more
wiley   +1 more source

The Effect of Empagliflozin on Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway in Patients with Type 2 Cardiorenal Syndrome. [PDF]

Anatol J Cardiol
Zhou P, Tang X, Deng Y, Wu R, Yi Y, Deng H, Cao Q.   +6 more
europepmc   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source

Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR. [PDF]

Ann Hematol
Lu Y, Lin L, Lin J, Wu B, Cai G, Wang X, Ma X.   +6 more
europepmc   +1 more source

IL-6; janus kinase-2 (JAK-2); JAK-3 [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema

Contact Dermatitis, EarlyView.
Patient‐reported outcomes are an important complement to physician‐assessed clinical outcome measures in Chronic Hand Eczema. In a pooled analysis of two randomised, controlled trials, twice‐daily treatment with delgocitinib cream 20 mg/g significantly improved the health‐related quality of life of patients with moderate to severe Chronic Hand Eczema ...
Andrea Bauer, Lyn Guenther, Richard Woolf, Eydna Didriksen Apol, Douglas Maslin, Nanna Nyholm, Henrik Thoning, Marie Louise Schuttelaar   +7 more
wiley   +1 more source